- Open Access
Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis
© Liang et al.; licensee BioMed Central Ltd. 2013
- Received: 24 January 2013
- Accepted: 22 May 2013
- Published: 25 May 2013
Deficiency in tuberin results in activation the mTOR pathway and leads to accumulation of cell matrix proteins. The mechanisms by which tuberin regulates fibrosis in kidney angiomyolipomas (AMLs) of tuberous sclerosis patients are not fully known.
In the present study, we investigated the potential role of tuberin/mTOR pathway in the regulation of cell fibrosis in AML cells and kidney tumor tissue from tuberous sclerosis complex (TSC) patients.
AML cells treated with rapamycin shows a significant decrease in mRNA and protein expression as well as in promoter transcriptional activity of alpha-smooth muscle actin (α-SMA) compared to untreated cells. In addition, cells treated with rapamycin significantly decreased the protein expression of the transcription factor YY1. Rapamycin treatment also results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells. Moreover, cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the αSMA promoter element in nuclear extracts of AML cells. Kidney angiomyolipoma tissues from TSC patients showed lower levels of tuberin and higher levels of phospho-p70S6K that resulted in higher levels of mRNA and protein of αSMA expression compared to control kidney tissues. In addition, most of the α-SMA staining was identified in the smooth muscle cells of AML tissues. YY1 was also significantly increased in tumor tissue of AMLs compared to control kidney tissue suggesting that YY1 plays a major role in the regulation of αSMA.
These data comprise the first report to provide one mechanism whereby rapamycin might inhibit the cell fibrosis in kidney tumor of TSC patients.
- YY1 and TSC
Tuberous Sclerosis complex (TSC) is a genetic disorder that causes tumors to form in many organs. Loss of heterozygosity (LOH) at the TSC1 or TSC2 loci has been detected in TSC-associated hamartomas and renal cell carcinoma (RCC) as well as in sporadic tumors of non-TSC patients [1, 2]. Kidney cancer development is rare in TSC, occurring in only 2–3% of all patients [3–5]. Multicentric angiomyolipomas are much more common in patients with TSC than RCCs, but may, nonetheless, have similar underlying genetic basis at early steps in their genesis and/or progression, specifically in the setting of tuberin deficiency . Angiomyolipomas (AMLs) are benign kidney tumors composed of smooth muscle, fat, and vessel cells. Renal angiomyolipomas tend to be larger, bilateral, multifocal and present at a younger age compared with sporadic forms . Angiomyolipomas most commonly occur in the kidneys and, although often asymptomatic, may enlarge and bleed leading to hemorrhage and renal impairment [8–10]. The lesions are usually benign although rare malignant cases have been described, often consisting of only the smooth muscle component .
The TSC2 gene product, tuberin, is a tumor suppressor protein whose absence or inactivation is associated with several defects such as abnormal cellular migration, proliferation, and differentiation [11–13]. Tuberin expression was initially induced following acute renal injury, suggesting that the TSC2 may function as an acute-phase response gene, limiting the proliferative response after injury . The smooth muscle cell component of angiomyolipoma is thought to derive from a precursor termed the perivascular epithelioid cell (PEC) . PEC-derived lesions, which include lymphangioleiomyomatosis (LAM), a cystic lung disease, are characterized by the dual expression of smooth muscle and melanocytic features . Angiomyolipoma is rare in the general population but is present in 80% of patients with TSC, an autosomal dominant tumor suppressor syndrome characterized by multiple hamartomas in the central nervous system, skin and other organs . Although TSC occurs equally in men and women, angiomyolipoma is more common and larger in women and is thought to be estrogen dependent. In vitro, the growth of cells derived from angiomyolipoma can be enhanced by estrogen . Thus, it is likely that although LAM and angiomyolipoma result from the loss of tuberin or hamartin. Unlike other TSC related hamartomas, their growth is promoted by estrogen.
The mammalian target of rapamycin (mTOR) serves a critical role in regulating the translational machinery that affects growth, proliferation, and differentiation, all of which are abnormally manifested in TSC lesions [19, 20]. These lesions are associated with accumulation of fibrotic proteins but the mechanisms by which tuberin regulates these proteins has not been explored. In the current study, we examined the role of tuberin/mTOR in regulating α-SMA in TSC patients. Here, we report for the first time that tuberin/mTOR pathways regulate α-SMA through redistribution the transcription factor YY1 from the cytoplasm to the nucleus in AML cells. In addition, binding of YY1 to α-SMA promoter may provide a mechanism for enhancing the expression α-SMA to increase cell fibrosis in kidney angiomyolipoma of TSC patients.
Inhibition of mTOR decreases protein and mRNA expression of αSMA
Rapamycin significantly decreased YY1 protein expression and αSMA promoter activity
To determine whether decreases in mRNA and protein expression were reflected in changes in αSMA promoter activity through YY1, AML cells were transfected with αSMA promoter luciferase construct. Cells treated with different concentrations of rapamycin (0-40 nM) for 24 h showed a significant decrease in YY1 protein expression by Western blot analysis (Figure 1C). YY1 is a potential transcription factor that regulates αSMA. In the next experiment we have tested the effect of rapamycin treatment on regulation of the promoter activity of αSMA in AML cells. A reporter plasmid containing the αSMA promoter driving expression of the luciferase and a control Renilla reporter gene were co-transfected into AML cells. Cells were treated with different concentrations of rapamycin (0-40 nM) for 24 h then luciferase activity was determined using the Luciferase Reporter Assay System by a luminometer and normalized by Renilla reporter activity. Data in Figure 1D showed that rapamycin treatment resulted in a significant decrease in αSMA promoter activity compared to untreated cells suggesting the role of mTOR in transcriptional regulation of αSMA.
Inhibition of mTOR results in redistribution of YY1 from the nucleus to cytoplasm in AML cells
Tuberin regulates αSMA
Rapamycin treatment significantly reduces the binding of YY1 to the αSMA promoter element
Mutation of YY1 reduces αSMA promoter activity
αSMA plasmid constructs contained wild type (WT) and mutant of YY1 driving expression of the luciferase were transfected into AML cells. A control Renilla reporter gene was co-transfected into AML cells. Luciferase activity was determined using the Luciferase Reporter Assay System by a luminometer and normalized by Renilla reporter activity. Data in Figure 4D showed that mutation in YY1 significantly decreased αSMA promoter activity and confirmed the role of YY1 in the regulation of transcriptional activity of αSMA.
Deficiency in tuberin and activation of mTOR result in increased YY1 in tumor kidney tissue of TSC patients
Upregulation of YY1 significantly increased in αSMA in tumor kidney tissues of TSC patient
This study provides the first evidence that tuberin regulates the expression and promoter activity of the cell fibrosis protein αSMA and that tuberin exerts this effect at least partially through the transcription factor, YY1. The data demonstrate that tuberin deficiency in AML cells is associated with upregulation of αSMA protein and mRNA, as well as with marked increase of αSMA promoter activity. Downregulation of tuberin in HEK293 renal cells is associated with increased protein expression of αSMA. These data indicate a novel role for tuberin in the regulation of cell fibrosis protein and provide a potential mechanism by which TSC2 mutations and tuberin deficiency predispose to the genesis and progression of fibrosis in kidney angiomyolipomas of TSC patients. Several approaches were utilized to conclusively demonstrate that tuberin/mTOR regulates αSMA. First, inhibition of mTOR by rapamycin was associated with decrease in αSMA mRNA and protein in AML cells. Second, inhibition of mTOR by rapamycin inhibits the promoter activity of αSMA in AML through decreased the protein expression of YY1. Third, rapamycin treatment resulted in redistribution of YY1 from the nucleus to cytoplasm in AML cells. Fourth, downregulation of tuberin in renal epithelial cells by siRNA against TSC2 was associated with increase in αSMA protein. Upregulation of tuberin by introduction of TSC2 cDNA into the tuberin-deficient cells into HEK293 cells results in significant decreased in αSMA protein expression. In addition, Inhibition of mTOR results in regulation the binding of YY1 to αSMA promoter to block fibrosis in AML cells. Mutation in YY1 blocked the binding of YY1 to αSMA promoter and resulted in significant decrease of αSMA promoter activity. Moreover, higher levels of mRNA and protein of αSMA were detected in kidney angiomyolipoma tissue compared to control kidney tissues. Furthermore, tumor tissue showed higher protein expression of YY1 compared to control kidney tissue suggesting that YY1 plays a major role in the regulation of fibrosis in kidney angiomyolipoma tissue.
In general, fibrosis results from activation and differentiation of fibroblasts, which overexpress extracellular matrix proteins including αSMA. The decrease in αSMA mRNA in AML cells suggests that decreased transcription is one potential mechanism responsible for downregulation of αSMA protein. YY1 has recently been shown to regulate the transcription of αSMA in lung fibroblast cells . YY1 binds to the αSMA promoter and activates αSMA transcription. The YY1 binds to αSMA promoter in the region between −556 and −526, which are important for binding of YY1 to the consensus sequence of αSMA promoter. Indeed, using EMSA, we found that YY1 binding was significantly decreased in AML cells treated with rapamycin. The specificity of the DNA protein complex was confirmed by demonstrating significant decrease in the binding of protein to DNA in the presence of anti-YY1antibody. Such antibodies did significantly block nuclear proteins from binding to αSMA promoter sites (Figure 3C). In addition, mutation in YY1 significantly decreased αSMA promoter activity in AML cells. Transcriptional activity using a heterologous αSMA-luciferase promoter in AML cells was also decreased in cells treated with rapamycin, clearly demonstrating that tuberin/mTOR regulates α-SMA through induction of its transcription. Collectively, the data indicate the major role of YY1 in the regulation of αSMA and fibrosis of kidney angiomyolipomas of TSC patients.
Our data showed that deficiency in tuberin and activation of mTOR resulted in upregulation of YY1 in tumor kidney tissue of TSC patients. The increase in mRNA and protein expression of αSMA was associated with increase of YY1 protein expression in tumor kidney tissues. In addition, the immunostaining data confirmed that most of blood vessel and smooth muscle cells were stained with αSMA in kidney tumor tissue. These data suggest that deficiency in tuberin resulted in upregulation αSMA and increased cell fibrosis through increased YY1 protein expression in kidney angiomyolipomas of TSC patients. Because YY1 can directly bind to the promoter regions of α-SMA gene  and is required for its expression, we suggest that YY1 directly regulates a-SMA that is involved in fibroblast activation and myofibroblast differentiation in kidney angiomyolipomas. Thus, decreasing YY1 expression may attenuate fibrotic responses by multiple mechanisms, in keeping with a growing role for YY1 in cell survival in response to injury [22, 23]. In addition to direct effects in fibroblasts, decreasing YY1 expression by rapamycin may inhibit early inflammation during injury and repair responses, and may help to protect against kidney fibrosis by this mechanism. In support of this idea, we showed that inhibition of mTOR by rapamycin decreased YY1 protein expression and significantly decreased the promoter activity of αSMA in AML cells. YY1 is generally considered a constitutively expressed nuclear phosphoprotein, but there is growing evidence that YY1 expression can be dynamically regulated by chemotherapy. Our data in Figure 2 showed the redistribution of YY1 from nucleus to cytoplasm in AML cells treated with rapamycin supporting this idea. In addition, case study showed that treatment of TSC patients with low dose of rapamycin reduced the facial angiofibromas, renal AML volume, improved of blood pressure control and absent bleeding over 12 months of treatment suggesting the role of rapamycin as an anti-fibrotic and anti-proliferative drug .
Kidney angiomyolipoma tissue from TSC patients with renal angiomyolipoma (total of 6) and unrelated healthy people (total of 6) were obtained from the Brain and Tissue Bank for Development Disorders (University of Maryland, Baltimore, Maryland, USA). The study has been approved by the Institutional Review Board of The University of Texas Health Science Center at San Antonio, TX.
Angiomyolipoma cells derived from kidney human of TSC patient were generously provided by Dr. Elizabeth Henske (Harvard Medical School, MA). The cells were grown in DMEM supplemented with 10% FBS. Human embryonic kidney epithelial cells (HEK293) were obtained from American Type Culture Collection (Manassas, VA) and maintained in DMEM with 10% FBS. All cell lines were grown at 37°C in a humidified atmosphere of 5% CO2.
Overexpression of tuberin
The human embryonic kidney (HEK293) cells were grown to 30–50% confluence, made quiescent by serum deprivation for 24 h and then infected at room temperature for 1 h with adenovirus 6.01 carrying the Tsc2 gene . Viral stocks were prepared and tittered using the serial dilution technique as described in the Adeno-X Expression Systems User Manual (Clontech Laboratories). Infection of cells with 20 multiplicity of infection (MOI) showed appreciable expression of TSC2 protein. An adenovirus vector expressing protein (Adβ-GAL) was used as a control. The cells were then incubated for 48 h at 37°C in a humidified atmosphere of 5% CO2. Cells were washed twice with PBS buffer and western blot analysis was performed on the cell extracts as above using tuberin and αSMA antibodies.
HEK293 cells were grown in six-well plates. Prior to transfection, cells (30–50% confluent) were washed with PBS and media was replaced with 800 μl of OPTI-MEM (Invitrogen, Carlsbad, CA). In parallel, 4 μl of oligofectamine (Invitrogen, NY) were combined with 11 μl of OPTI-MEM I and incubated at room temperature for 10 min. SMART selected small interfering RNA (siRNA) duplexes of TSC2 with ‘UU’ overhangs and 5′ phosphate on the antisense strand. The siRNA specific for TSC2 was a mixture of four pooled duplexes. The TSC2 siRNA kit was obtained from Dharmacon/Upstate, (Lake Placid, NY). According to the manufacturer, these siRNA efficiently blocks tuberin expression by 50–70%. The indicated duplex of 1.5 μg were diluted into 180 μl of OPTI-MEM I, added to the Oligofectamine/OPTI-MEM I mixture and incubated at room temperature for 20 min. The siRNA complexes were then added to the cells. After incubation for 3–4 h in a 5% CO2 incubator, 1 ml of fresh medium was added to a final serum concentration of 10%. Forty-eight hours after transfection, cells were harvested for western blot analysis. The control construct used in parallel experiments contains four, pooled, non-specific siRNA duplexes provided by with the kit .
Homogenates of kidney cortex or cell lysates were prepared as described previously . Protein concentrations were determined with the Bradford assay using bovine serum albumin as a standard . Western blot analysis was performed as described previously . Tuberin, phospho-p70S6K, and p70S6K antibodies were from Cell Signaling (Boston, MA); GADPH and antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and Actin antibody from Calbiochem (Billerica, MA). αSMA rabbit antibody was from Abcam (Cambridge, MA). An enhanced chemiluminescence kit (Amersham, NJ) was used to identify protein expression. Expression of each protein was quantified by densitometry using National Institutes of Health image 1.62 software and normalized to a loading control.
Electrophoretic mobility shift assay
Nuclear proteins were extracted from AML cells as described previously . The protein concentration of the nuclear extracts was determined using Bradford method . Electrophoretic mobility shift assay (EMSA)-binding reactions were incubated in a 20 μl final volume for 20 min at room temperature containing 5 μg of the nuclear extract, 20–30 fmol of the 5′ end-labeled double-stranded 21 bp oligonucleotide: 5’- AGTTCCTGGTTTCATTACTACAACACAA −3, covering the region of the αSMA promoter from 556 to 526 (control), and 1 μl of poly (dI-dC). Mutant oligonucleotide was designed as following: 5’- AGTTCCTGGAAA CATTACTACAACACAA −3. The super shift assays were performed by pre-incubating nuclear extracts with 1 μg of YY1 antibody (Santa Cruz Biotechnology) into the reaction. In addition, labeled YY1 oligonucleotide at 556 to 526 (nt)- was incubated with nuclear extracts of AML cells. The reaction was carried out at room temperature for 30 min prior to adding the radiolabelled probe. The complexes were resolved using a 5% non-denaturing polyacrylamide gel. The gels were dried and exposed overnight at −70°C.
Immunofluorescence staining of YY1
A double fluorescence labeling method was used as described previously with minor modifications . AML cells in chamber slides were serum-starved for overnight then treated with different concentrations of rapamycin (0-40 nM) for 24 hours. The cells were washed with PBS, fixed, and incubated with rabbit antibody against YY1 (Cell Signaling Technology, MA), followed by secondary anti-rabbit IgG conjugated with FITC. The cells were reacted with Vectashield Mounting Medium with Propedium Iodide (PI) (Vector Laboratories). In this assay, DNA was labeled with PI, and YY1 was identified by the primary monoclonal antibody FITC green signals. FITC green signals for YY1 were detected using a filter with excitation range 450–490 nm and propidium iodide red signals for nuclear DNA using a filter with excitation at 535 nm. FITC and propidium iodide were detected using an Olympus Research microscope equipped for epifluorescence with excitation and band pass filters. To show staining specificity, control cells were stained without primary antibody.
Immunoperoxidase staining of αSMA
Detection of αSMA was performed on paraffin sections of normal and tumor kidney by immunoperoxidase histochemical staining . Kidney sections underwent a protease digestion step before they were incubated with rabbit anti-αSMA antibody (Abcam, Cambridge, MA) for 30 min then washed twice with PBS. Sections were then incubated with horseradish peroxidase labeled anti-rabbit antibody for 30 min. The horseradish peroxidase was developed with diaminobenzidine tetrahydrochloride and hydrogen peroxide in PBS. Control sections in both procedures were incubated without primary antibody.
Cell lysates fractionation
Cytoplasmic and nuclear protein fractions were extracted from the cell lysates using a nuclear and cytoplasmic fractionation kit (Pierce, Rockford, IL). The protein concentration of the nuclear extracts was determined using the Bradford method .
Quantitation of mRNA by RT-PCR
RNA was isolated from cells treated with rapamycin (0-40 nM) using RNA Isolation Solvent (Tel-Test, Newark, NJ). In addition, RNA was extracted from kidney tissue of control and tumors samples using RNeasy Mini kit (Qiagen, Valencia, CA). RNA was quantitated by spectrophotometery at 260 nm, and its integrity tested by formaldehyde/agarose gel electrophoresis. RTPCR was performed as previously described using the primers (5’-3-ACGCTGGTCACCGTGGCGGC/5’- TTGCCGCTCTTCTTGCCGCC) for αSMA. The amplified product was 356-bp long. For GAPDH, an internal control of amplification, upstream/reverse primers were 5'- GCCACCCAGAAGACTGTGGAT /5'- GAAGGCCATGCCAGTGAGCT synthesizing a 528-bp product. The PCR products were analyzed by electrophoresis on agarose gels and ethidium bromide staining. The yield was determined by densitometry and the ratio of αSMA to actin was then calculated.
Transcriptional activity of αSMA promoter
A mouse αSMA promoter reporter plasmid was used to determine the transcriptional activity of the αSMA gene. αSMA plasmid constructs contained wild type or mutant of YY1 were generously provided by Dr. Jia Guo (University of Rochester Medical School, Rochester, New York). A Renilla reporter plasmid (pRL-null) was used as transfection control. Plasmids were transfected into PPTE cells using the LipofectAMINE and Plus Reagent method (Life Technologies, NY). LipofectAMINE was added to the complex of DNA and Plus reagent and incubated for 15 min at room temperature. DNA and Plus reagent-LipofectAMINE complexes were added to each well and incubated at 37°C with 5% CO2. After incubation for 3–4 h, 1 ml of fresh media with 20% serum was added to a final concentration of 10%. Cells were pre-treated with rapamycin (0-40 nM) for 24 h. Forty-eight hours after transfection, cells were harvested for Firefly and Renilla luciferase assay using Dual-Luciferase Reporter assay kit (Promega, Madison, WI). Luciferase activity was determined using the Luciferase Reporter Assay System and a Turner luminometer according to the manufacturer's instructions (Promega, Madison, WI) and normalized to Renilla activity.
Data are presented as mean ± standard error. Statistical differences were determined using ANOVA followed by Student Dunnett’s (Exp. vs. Control) test using 1 trial analysis. P- values less than 0.05 and 0.01 were considered statistically significant.
This work was supported in part by grants from the American Heart Association, American Diabetes Association and Merit Review Award from South Texas Veterans Healthcare System (to S.L.H.).
- Osborne JP, Fryer A, Webb D: Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991, 615: 125-127. 10.1111/j.1749-6632.1991.tb37754.xView ArticlePubMedGoogle Scholar
- Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355: 1345-1356. 10.1056/NEJMra055323View ArticlePubMedGoogle Scholar
- Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP: Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998, 83: 2208-2216. 10.1002/(SICI)1097-0142(19981115)83:10<2208::AID-CNCR21>3.0.CO;2-KView ArticlePubMedGoogle Scholar
- Parry L, Maynard JH, Patel A, Clifford SC, Morrissey C, Maher ER, Cheadle JP, Sampson JR: Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br J Cancer. 2001, 85: 1226-1230. 10.1054/bjoc.2001.2072PubMed CentralView ArticlePubMedGoogle Scholar
- Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP: Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Canc. 1995, 13: 295-298. 10.1002/gcc.2870130411.View ArticleGoogle Scholar
- Astrinidis A, Henske EP: Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005, 24: 7475-7481. 10.1038/sj.onc.1209090View ArticlePubMedGoogle Scholar
- Jozwiak J: Hamartin and tuberin working together for tumor suppression. Int J Cancer. 2006, 118: 1-5. 10.1002/ijc.21542View ArticlePubMedGoogle Scholar
- Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000, 97: 6085-6090. 10.1073/pnas.97.11.6085PubMed CentralView ArticlePubMedGoogle Scholar
- Stillwell TJ, Gomez MR, Kelalis PP: Renal lesions in tuberous sclerosis. J Urol. 1987, 138: 477-481.PubMedGoogle Scholar
- Shapiro RA, Skinner DG, Stanley P, Edelbrock HH: Renal tumors associated with tuberous sclerosis: the case for aggressive surgical management. J Urol. 1984, 132: 1170-1174.PubMedGoogle Scholar
- Li Y, Inoki K, Guan KL: Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol. 2004, 24: 7965-7975. 10.1128/MCB.24.18.7965-7975.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002, 10: 151-162. 10.1016/S1097-2765(02)00568-3View ArticlePubMedGoogle Scholar
- Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2002, 277: 35364-35370. 10.1074/jbc.M205838200View ArticlePubMedGoogle Scholar
- Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002, 4: 648-657. 10.1038/ncb839View ArticlePubMedGoogle Scholar
- Rennebeck G, Kleymenova EV, Anderson R, Yeung RS, Artzt K, Walker CL: Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryoni c lethality characterized by disrupted neuroepithelial growth and development. Proc Natl Acad Sci USA. 1998, 95: 15629-15634. 10.1073/pnas.95.26.15629PubMed CentralView ArticlePubMedGoogle Scholar
- Plank TL, Logginidou H, Klein-Szanto A, Henske EP: The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas. Mod Pathol. 1999, 12: 539-545.PubMedGoogle Scholar
- Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP: Tuberous sclerosis-associated renal cell carcinoma: clinical, pathological, and genetic features. Am J Pathol. 1996, 149: 1201-1208.PubMed CentralPubMedGoogle Scholar
- Robb VA, Astrinidis A, Henske EP: Frequent hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol. 2006, 19: 839-4.View ArticlePubMedGoogle Scholar
- Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP: Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007, 67: 7106-7112. 10.1158/0008-5472.CAN-06-4798View ArticlePubMedGoogle Scholar
- Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17: 1829-1834. 10.1101/gad.1110003PubMed CentralView ArticlePubMedGoogle Scholar
- Lin X, Sime PJ, Xu H, Williams MA, LaRussa L, Georas SN, Guo J: Yin yang 1 is a novel regulator of pulmonary fibrosis. Am J Respir Crit Care Med. 2011, 183: 1689-1697. 10.1164/rccm.201002-0232OCPubMed CentralView ArticlePubMedGoogle Scholar
- Roy SG, Nozaki Y, Phan SH: Regulation of alpha-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int J Biochem Cell Biol. 2001, 33: 723-734. 10.1016/S1357-2725(01)00041-3View ArticlePubMedGoogle Scholar
- Riquet FB, Tan L, Choy BK, Osaki M, Karsenty G, Osborne TF, Auron PE, Goldring MB: YY1 is a positive regulator of transcription of the Col1a1 gene. J Biol Chem. 2001, 276: 38665-38672. 10.1074/jbc.M009881200View ArticlePubMedGoogle Scholar
- Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R: Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Nephrol Dial Transplant. 2010, 25: 3787-3791. 10.1093/ndt/gfq456View ArticlePubMedGoogle Scholar
- Habib SL, Riley DJ, Mahimainathan L, Bhandari B: Tuberin regulates the DNA repair enzyme OGG1. Am J Physiol Renal Physiol. 2008, 294: F281-F289.View ArticlePubMedGoogle Scholar
- Habib SL, Bhandari BK, Sadek N: Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells. Carcinogenesis. 2010, 31: 2022-2030. 10.1093/carcin/bgq189PubMed CentralView ArticlePubMedGoogle Scholar
- Habib SL, Phan MN, Patel SK, Li D, Monks TJ, Lau SS: Reduced constitutive 8-oxoguanine-DNA glycosylase expression and impaired induction following oxidative DNA damage in the tuberin deficient Eker rat. Carcinogenesis. 2003, 24: 573-582. 10.1093/carcin/24.3.573View ArticlePubMedGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3View ArticlePubMedGoogle Scholar
- Habib SL, Simone S, Barnes JJ: Tuberin Haploinsufficiency is Associated with the Loss of OGG1 in Rat Kidney Tumors. Mol Cancer. 2008, 7: 10-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Habib SL, Yadav M, Tizani S, Bhandari B, Valente AJ: Tuberin inhibits production of the matrix protein fibronectin in diabetes. J Am Soc Nephrol. 2012, 23: 1652-1662. 10.1681/ASN.2012030285PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.